跳到正文
原文
MedPage Today·· 2 小时前精选AI 评分75

前列腺癌筛查正在改变,医疗系统必须跟上

Prostate Cancer Screening Is Changing. Health Systems Must Catch Up.

AI 导读

美国癌症协会建议50至69岁男性每2年进行一次PSA检测,45岁及以下有家族史的黑人男性每年检测一次。MRI等新技术有助于减少不必要的活检和治疗。文章强调了保险覆盖、可靠转诊路径和持续监测的重要性。

推荐理由

文章总结了前列腺癌筛查的新指南,并强调了提高筛查和诊断过程的可及性和安全性。

正文 · 原文

— Better preventive tools should be accompanied by accessible and affordable follow-up

by Gilberto de Lima Lopes Junior, MD, MBA

November 20, 2026 • 5 min read

For years, the medical community has been divided on prostate cancer screening. Urology organizations have continued to recommend prostate-specific antigen (PSA) testing, while other societies and groups moved to emphasize shared decision-making and individual choice, after careful consideration of potential risks and benefits.

The American Cancer Society's (ACS) new recommendations incorporate updated data and make a clearer suggestion in favor of screening. Longer follow-up research has confirmed that screening prevents prostate cancer deaths, and advances in diagnosis and treatment reduce complications.

To support that recommendation, we must make the safer approach available wherever men receive care.

ACS now recommends a PSA blood test every 2 years for average-risk men ages 50 through 69, and annually beginning at 45 for Black men and men with a strong family history. Decisions at 70 through 74 should be individualized. Informed patient agreement remains essential, and screening recommendations generally stop at 75 or when life expectancy is under 10 years.

The strongest evidence for this change comes from the European randomized screening trial. After 23 years, men invited to repeated PSA screening had a 13% lower risk of dying from prostate cancer. The absolute reduction was 0.22 percentage points: approximately two fewer deaths per 1,000 men invited. One death was prevented for every 456 men invited to screening. That benefit is meaningful, but modest.

Screening also finds cancers that would never threaten a man's life. Reasonable experts weigh those trade-offs differently: the U.K. National Screening Committee recently declined to recommend population screening. Recommendations for earlier screening in Black men also rely substantially on modeling because trials inadequately represent them. Supporting the new recommendations requires that we acknowledge these uncertainties.

What strengthens the case for screening today is our growing ability to separate an elevated PSA from a mandatory biopsy, and a cancer diagnosis from an automatic, potentially debilitating treatment.

An elevated PSA should first be confirmed before further evaluation. MRI can then help determine who needs a biopsy. In the Göteborg-2 randomized trial, an MRI-directed approach reduced detection of clinically insignificant cancers by 57% compared with routine systematic biopsy. That finding supports a more selective diagnostic process, although it does not yet prove equivalent long-term survival.

Biopsy itself can be made safer. Transperineal biopsy reaches the prostate through the skin rather than the rectum (e.g. transrectal biopsy, which is the historically more common approach). In the PREVENT randomized trial, infections occurred in none of the men receiving this approach without preventive antibiotics, compared with 1.6% undergoing transrectal biopsy with targeted antibiotics. Cancer detection was similar.

For appropriately selected low-risk cancers, active surveillance can spare or postpone treatment. In the prospective Canary PASS study, estimated prostate cancer mortality at 10 years was 0.1%, and metastasis occurred in 1.4%. About half had received treatment by then. Surveillance means scheduled reassessment and intervention when warranted; its safety depends on continued and adequate follow-up.

Treatment is improving too. In the randomized MIRAGE trial, MRI-guided radiation with smaller treatment margins reduced cumulative moderate-or-worse urinary toxicity over 2 years from 51% to 27%, compared with CT-guided treatment. Bowel toxicity also fell. These results support precision in radiation delivery, while longer follow-up remains important.

In surgery for radical prostatectomy, the NeuroSAFE PROOF trial used rapid examination of tissue during the operation to guide nerve preservation. Among men with good erectile function beforehand, the approach improved erectile-function scores 1 year later and early continence recovery. Neither technique eliminates treatment harms, but both show that preserving quality of life can be a measurable treatment objective.

Aligning these advances with a safe screening program requires changes in how we deliver and pay for care.

First, insurers should cover the entire recommended evaluation without financial barriers: repeat PSA testing, appropriate MRI or biomarkers, and biopsy when indicated. A study of privately insured men found that median out-of-pocket spending for MRI plus biopsy reached up to $620 in 2020. A screening recommendation loses value when patients cannot afford the steps needed to interpret its result safely. Making this a nationwide requirement may take an updated U.S. Preventive Services Task Force recommendation with an A or B grade, explicit protection for follow-up testing, or legislation. The task force's current C grade does not trigger the Affordable Care Act's no-cost preventive coverage requirement.

Second, health systems need reliable referral pathways. Primary care teams should know where to send patients, who tracks abnormal results, and how quickly evaluation should occur. MRI quality and interpretation require oversight. A negative scan cannot become a reason to abandon follow-up when other findings remain concerning. Regional imaging networks, specialist consultation and patient navigation can help extend expertise beyond major cancer centers.

Third, active surveillance must be supported as ongoing care. Patients need understandable explanations, dependable recall systems, and accessible reassessment. Payment should recognize the clinical work involved in monitoring a cancer carefully. Men also should have access to balanced consultations about surgery and radiation, including likely effects on sexual, urinary, and bowel function.

Finally, health systems need to measure whether screening delivers better outcomes. Quality programs should track unresolved abnormal results, biopsy-related infections, surveillance participation, treatment complications, and diagnoses of metastases. Results should be examined by ethnicity, insurance, and geography to identify gaps and guide improvement. Research programs should also expand enrollment of Black men in screening and surveillance studies, so future recommendations rest on evidence that better represents those at greatest risk.

I support the ACS recommendations. We now have stronger evidence that screening saves lives and better tools to reduce its harms. We need to make those tools available to every man we screen, with affordable follow-up, careful decisions about treatment, and support throughout his care.

来源:MedPage Today · medpagetoday.com